/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Incannex Healthcare Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.4511 0.1268(12.68%) IXHL at 04 Dec 2025 04:35 PM Drug Manufacturers - Specialty & Generic
Lowest Today 0.4048
Highest Today 0.4897
Today’s Open 0.4886
Prev. Close 0.3966
52 Week High 2.25
52 Week Low 0.08
Day’s Range: Low 0.4048 High 0.4897
52-Week Range: Low 0.08 High 2.25
1 day return -
1 Week return +23.78
1 month return +31.95
3 month return -20.78
6 month return +141.73
1 year return -73.13
3 year return -97.04
5 year return -
10 year return -

Institutional Holdings

AdvisorShares Psychedelics ETF 0.45

AdvisorShares Investments, LLC 0.37

LPL Financial Corp 0.35

Fidelity Nasdaq Composite Index 0.12

Wealth Enhancement Advisory Services, LLC 0.10

UBS Group AG 0.08

Commonwealth Equity Services Inc 0.06

Scientech Research LLC 0.04

Morgan Stanley - Brokerage Accounts 0.03

Citigroup Inc 0.03

Barclays PLC 0.02

Revisor Wealth Management LLC 0.02

SBI Securities Co Ltd 0.00

Iron Horse Wealth Management, LLC 0.00

Bridgeway Capital Management, LLC 0.00

Citadel Advisors Llc 0.00

Jane Street Group LLC 0.00

Squarepoint Ops LLC 0.00

Market Status

Fundamentals

Market Cap 137.31 M

PB Ratio 1.597

PE Ratio 0.0

Enterprise Value 49.91 M

Total Assets 20.45 M

Volume 220920257

Company Financials

Annual Revenue FY25:86000 0.1M, FY24:12000 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:1897596 1.9M

Annual Profit FY25:86000 0.1M, FY24:12000 0.0M, FY23:0 0.0M, FY22:-6338 -0.0M, FY21:985628 1.0M

Annual Net worth FY25:-46885000 -46.9M, FY24:-18459000 -18.5M, FY23:-19979558 -20.0M, FY22:-15025993 -15.0M, FY21:-8160911 -8.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:74000 0.1M, Q1/2025:0 0.0M, Q4/2024:12000 0.0M, Q3/2024:74000 0.1M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:66616 0.1M, Q1/2025:null 0.0M, Q4/2024:12000 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q3/2025:-6407000 -6.4M, Q2/2025:-35572000 -35.6M, Q1/2025:-6626917 -6.6M, Q4/2024:-5894000 -5.9M, Q3/2024:-5420000 -5.4M

Fund house & investment objective

Company Information Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Organisation Drug Manufacturers - Specialty & Generic

Employees 12

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Joel Bradley Latham

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow